INTIOTCPharmaceutical PreparationsFiscal year ends December 31
Inhibitor Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.11+0.00 (+0.09%)
Close on Oct 19, 2026
- Market cap
- $19.06M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.0620 (+129.2%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $19.06M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$3.31M
- EPS, diluted
- -$0.01
- Book value per share
- -$0.01
- Diluted shares
- 173M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$3.37M
Net income
-$3.31M
EPS, diluted
-$0.01
Reported periodTrailing twelve months